Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
CAR-T Cell Therapy for Kidney Transplant Desensitization
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial tests a new product, CART BCMA + huCART-19, to reduce cPRA in people who have been waiting for a kidney transplant for at least a year and have an immune system that would reject 99.5% of available kidneys. It will test safety & feasibility over a two-year period & followed up to 15 years.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service